Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
WuXi AppTec Immune Profiling in Drug Discovery

(1)  Tissue-based immune profiling
  • Various tissue staining (IHC/IF) and whole slide image analysis platform

(2)  Cell-based immune profiling and cytokine/chemokine profiling
  • TIL analysis by FACS
  • MSD and Luminex multiplex detection system

(3)  RNA-based immune profiling
  • Single cell RNA sequencing platform
  • NanoString technology platform

Targeted Oncology

(1)  CLDN18.2 related CDX models
  • NUGC4 gastric cancer CDX model, tested with IMAB362

(2)  Engineered cell line/model overexpressing human CLDN18.2 (hCLDN18.2)
  • hCLDN18.2/MIA PaCa-2 model, tested with IMAB362
  • hCLDN18.2/NCI-N87 model, tested with IMAB362 analog
  • hCLDN18.2/BxPC-3 model, tested with IMAB362 analog

(3)  CLDN18.2 related PDX models
  • 8 pancreatic cancer and 5 gastric cancer PDX models with CLDN18 overexpression

RAF-MEK1/2 Related In Vivo Models

(1)  RAF-MEK1/2 related CDX models
  • HT29 colon cancer, A375 melanoma, A549 and NCI-H358 lung cancer CDX models, tested with Trametinib
  • COLO 829 melanoma and DU4475 breast cancer CDX models, tested with Dabrafenib
  • COLO 205 colon cancer and SK-MEL-28 melanoma CDX models, carrying BRAF V600E mutation

(2)  RAF-MEK1/2 related PDX models
  • 7 PDX models covering melanoma, pancreatic cancer and colon cancer, carrying BRAF V600E mutation
  • ME-21-0001 melanoma PDX model, tested with Dabrafenib

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.
Best regards,
WuXi AppTec OncoWuXi Team